Effect of Pam3Cys induced protection on the therapeutic efficacy of miltefosine against experimental visceral leishmaniasis

Peptides

Volumn 32, Issue 10, 2011, Pages 2131-2133

  Shakya, Nishi ^a   Sane, Shraddha A ^a   Shankar, Shagun ^a   Gupta, Suman ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEISHMANIAL AGENT; LIPOPEPTIDE; MILTEFOSINE; PAM3CYS PROTEIN; UNCLASSIFIED DRUG;

AMASTIGOTE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; EVALUATION; FEMALE; LEISHMANIA DONOVANI; LOW DRUG DOSE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; VISCERAL LEISHMANIASIS;

ANIMALS; ANTIPROTOZOAL AGENTS; CRICETINAE; CYSTEINE; FEMALE; LEISHMANIASIS, VISCERAL; LIPOPROTEINS; MALE; MICE; MICE, INBRED BALB C; PHOSPHORYLCHOLINE;

BACTERIA (MICROORGANISMS); LEISHMANIA DONOVANI; RODENTIA;

EID: 80054072670     PISSN: 01969781     EISSN: 18735169     Source Type: Journal    
DOI: 10.1016/j.peptides.2011.09.014     Document Type: Article

References (13)

1. R.D. Astronomo, and D.R. Burton Carbohydrate vaccines: developing sweet solutions to sticky situations? Nat Rev Drug Discov 9 2010 308 324
2. C. Bogdan Mechanisms and consequences of persistence of intracellular pathogens: leishmaniasis as an example Cell Microbiol 10 2008 1221 1224
3. T. Buskas, S. Ingale, and G-J. Boonsa Glycopeptides as versatile tools for glycobiology Glycobiology 16 2006 113R 136R (Pubitemid 44288233)
4. T. Buskas, P. Thompsona, and G-J. Boonsa Immunotherapy for cancer: synthetic carbohydrate-based vaccines Chem Commun 28 36 2009 5335 5349
5. F. Chappuis, S. Sundar, A. Hailu, H. Ghalib, S. Rijal, and R.W. Peeling Visceral leishmaniasis, what are the needs for diagnosis, treatment and control? Nat Rev Microbiol 5 2007 873 882 (Pubitemid 47578388)
6. M.L. den Boer, J. Alvar, R.N. Davidson, K. Ritmeijer, and M. Balasegaram Developments in the treatment of visceral leishmaniasis Expert Opin Emerg Drugs 14 2009 395 410
7. Z. Guo, and Q. Wang Recent development in carbohydrate-based cancer vaccines Curr Opin Chem Biol 13 5-6 2009 608 617
8. S. Gupta, Ramesh, S.C. Sharma, and V.M.L. Shrivastava Efficacy of picroliv combination with miltefosine, an orally effective antileishmanial drug against experimental visceral leishmaniasis Acta Trop 94 2005 41 47 (Pubitemid 40445378)
9. S.A. Sane, N. Shakya, W. Haq, and S. Gupta CpG oligodeoxynucleotide augments the antileishmanial activity of miltefosine against experimental visceral leishmaniasis J Antimicrob Chemother 65 2010 1448 1454
10. P. Sharma, N. Singh, R. Garg, W. Haq, and A. Dube Efficacy of human β-casein fragment (54-59) and its synthetic analogue compound 89/215 against Leishmania donovani in hamsters Peptides 25 2004 1873 1881 (Pubitemid 39389181)
11. P.A. Sieling, W. Chung, B.T. Duong, P.J. Godowski, and R.L. Modlin Toll-like receptor 2 ligands as adjuvants for human Th1 responses J Immunol 170 2003 194 200 (Pubitemid 36026140)
12. V. Yardley, A.A. Khan, M.B. Martin, T.R. Slifer, F.G. Araujo, and S.N.J. Moreno In vivo activities of farnesyl pyrophosphate synthase inhibitors against Leishmania donovani and Toxoplasma gondii Antimicrob Agents Chemother 46 2002 929 931 (Pubitemid 34157693)
13. W. Zeng, S. Ghosh, Y.F. Lau, L.E. Brown, and D.C. Jackson Highly immunogenic and totally synthetic lipopeptides as self-adjuvanting immunocontraceptive vaccines J Immunol 169 2002 4905 4912 (Pubitemid 35217155)